title: [Clinicopathological analysis of 80 patients with duodenum gastrointestinal stromal tumors].
abstract: OBJECTIVE
  To explore the clinicopathological characteristics, efficacy, and prognostic factors for patients with duodenum gastrointestinal stromal tumor(GIST).
  
  
  METHODS
  Clinicopathological and follow-up data of 80 patients with duodenum GIST in the Zhongshan Hospital from January 2000 to December 2013 were analyzed retrospectively.
  
  
  RESULTS
  There were 38 male and 42 female patients with a median age of 54 years. The major symptoms were upper alimentary tract hemorrhage and abdominal pain. Thirty-nine patients received local tumor excision, 18 patients underwent segmental duodenectomy, 23 patients were subjected to pancreaticoduodenectomy, all these operations were R0 resection. Thirty patients received imatinib treatment after operation, and 11 among them had metastasis relapse. Recurrence-free survival rates of 1-, 3-, and 5-years were 96.2%, 90.6%and 78.6% retrospectively. Overall survival rates of 1-, 3-, and 5-years were 100%, 98.3% and 96.1%. Multivariate Cox analysis showed tumor size >5 cm, mitotic count >5 mitosis/50 HPF and intermediate/high NIH risk classification were associated with an increased risk of recurrence. The significant difference was not detected between the limited resection group and pancreaticoduodenectomy group in OS and RFS.
  
  
  CONCLUSIONS
  Surgery is still the main treatment for duodenum GIST. The surgical program is mainly determined by the location and size of tumor. Imatinib therapy should be used if necessary.
authors: Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. shen.kuntang@zs-hospital.sh.cn.
authors: Yong
authors: Y
authors: Fang
authors: Kuntang
authors: K
authors: Shen
authors: Anwei
authors: A
authors: Xue
authors: Jiaqian
authors: J
authors: Ling
authors: Xiaodong
authors: X
authors: Gao
authors: Ping
authors: P
authors: Shu
authors: He
authors: H
authors: Li
authors: Yingyong
authors: Y
authors: Hou
authors: Jing
authors: J
authors: Qin
authors: Yihong
authors: Y
authors: Sun
authors: Xinyu
authors: X
authors: Qin
mesh_terms: D015746:Abdominal Pain; D001549:Benzamides; D004379:Duodenal Neoplasms; D005260:Female; D006471:Gastrointestinal Hemorrhage; D046152:Gastrointestinal Stromal Tumors; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D016577:Pancreaticoduodenectomy; D010879:Piperazines; D011379:Prognosis; D011743:Pyrimidines; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate